Compare TECH & LNTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TECH | LNTH |
|---|---|---|
| Founded | 1976 | 1956 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.6B | 5.6B |
| IPO Year | 1995 | 2014 |
| Metric | TECH | LNTH |
|---|---|---|
| Price | $43.42 | $94.07 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 11 | 6 |
| Target Price | $71.82 | ★ $87.00 |
| AVG Volume (30 Days) | ★ 2.8M | 795.5K |
| Earning Date | 05-06-2026 | 05-07-2026 |
| Dividend Yield | ★ 0.62% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | 0.81 | ★ 1.80 |
| Revenue | ★ $1,219,635,000.00 | $343,374,000.00 |
| Revenue This Year | $2.49 | N/A |
| Revenue Next Year | $6.40 | $14.19 |
| P/E Ratio | $55.27 | ★ $53.62 |
| Revenue Growth | ★ 5.23 | 3.62 |
| 52 Week Low | $44.12 | $47.27 |
| 52 Week High | $72.16 | $98.27 |
| Indicator | TECH | LNTH |
|---|---|---|
| Relative Strength Index (RSI) | 32.35 | 67.50 |
| Support Level | N/A | $72.35 |
| Resistance Level | $58.41 | N/A |
| Average True Range (ATR) | 3.19 | 3.21 |
| MACD | -1.08 | 0.76 |
| Stochastic Oscillator | 1.31 | 77.00 |
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. It reports in two segments: protein sciences (about 75% of revenue) and diagnostics and genomics (25%). The protein sciences segment sells reagents and analytical instruments used in life sciences research, including antibodies used in protein analysis. The diagnostics and genomics segment sells diagnostic reagents, molecular diagnostics, and spatial biology products. The United States accounts for about 55% of revenue. The firm also has operations in Europe, the Middle East, and Africa (20% of sales), the UK (5%), and Asia-Pacific (15%), with the rest of the world accounting for the remaining 5%.
Lantheus Holdings Inc is a radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver patient outcomes. The Company classifies its products into Radiopharmaceutical Oncology, Precision Diagnostics, and Strategic Partnerships and Other Revenue. Its products help healthcare professionals Find, Fight and Follow cancer and diseases and are used by physicians and technologists in clinical settings. The Company produces and markets its products in the United States, mainly to hospitals, independent imaging centers and government facilities, and sells outside the United States through direct and third-party distribution relationships and licensing arrangements in Europe, Canada, Australia, Asia-Pacific, Central America and South America.